Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP, and Amy Barker, MSN, APRN, FNP-CWe have witnessed dismal overall outcomes in individuals with relapsed and/or refractory (R/R) multiple myeloma (MM) for many years. However,…
Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP The bispecific antibodies have shown an impressive response rate with tolerable safety profile in patients with relapsed and refractory multiple myeloma (R/R MM). The Food…
Stephen Michael Clark, PharmD BCOP There have been some exciting advancements in immunotherapy for cancer in the past year, particularly hematologic malignancies. One such advancement is a group of therapies…
Kim Navarrete, MSN, APRN, FNP-C, OCN, and Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP Multiple myeloma (MM) is a hematologic malignancy associated with the clonal proliferation of plasma cells. Despite decades of…
Karla V. Ow, MSN, FNP, AOCNP Chimeric antigen receptor (CAR) T cells are lymphocytes that have been genetically modified to produce a CAR that specifically targets tumor cell antigens.1 CAR…
Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP The Food and Drug Administration approved Carvykti (ciltacabtagene autocleucel, Janssen Biotech Inc.) in February 2022 making it the second chimeric antigen receptor (CAR) T-cell therapy…
Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP Multiple myeloma (MM) is the second most common hematological malignancy; it is characterized by the clonal proliferation of plasma cells, and it is incurable. Despite…
Glen J Peterson, RN, DNP, ACNP and Jessica Casselberry, MSN, ANP-BC, AOCNP A thorough assessment of the patient with a hematologic malignancy is essential for the delivery of quality care.…
Abigail Shockley, PharmD Chimeric antigen receptor T (CAR-T) therapies have resulted in durable remissions for patients with refractory hematologic malignancies; however, patients can experience many side effects following administration. Cytokine…
Elizabeth S. Waxman, BSN, RN, MSN, ANP-BC Hemophagocytic lymphohistiocytosis (HLH) is a rare, potentially fatal syndrome characterized by unchecked and persistent activation of cytotoxic T cells and natural killer (NK)…